Prophylaxis with caspofungin for invasive fungal infections in high-risk liver transplant recipients.
OBJECTIVE
The aim of this prospective, multicenter, noncomparative, open-label trial was to evaluate the prophylactic use of caspofungin in adult liver transplant recipients at high risk of developing invasive fungal infections (IFI).


METHODS
Patients received caspofungin for at least 21 days. A successful treatment outcome was defined as the absence of breakthrough IFI during the first 100 days after the onset of caspofungin.


RESULTS
According to study design, 71 patients were included. In the modified intention-to-treat analysis, successful treatment outcome was obtained in 88.7%. Two patients developed IFI: a Mucor and a Candida albicans surgical wound infections, respectively. Six more patients discontinued caspofungin because of drug-related altered liver function. No clinical side effects were related to caspofungin. Altered analytical data compatible with grade IV toxicity, irrespective of caspofungin attribution, were observed in 27.7% of patients at the end of caspofungin prophylaxis and in 15.4% of patients in safety visit (14 days after ending caspofungin administration) (P=0.13). Eight patients died, six during caspofungin administration and two during follow-up period, but none were attributed to IFI or caspofungin toxicity.


CONCLUSIONS
These results show that caspofungin could be considered an efficacious and well-tolerated drug as antifungal prophylaxis in high-risk liver transplant recipients.
Fortún
Jesus
J
Department of Infectious Diseases, Ramón y Cajal Hospital, Madrid, Spain. fortun@ono.com
Martín-Dávila
Pilar
P
Montejo
Miguel
M
Muñoz
Patricia
P
Cisneros
José M
JM
Ramos
Antonio
A
Aragón
Cesar
C
Blanes
Marino
M
San Juan
Rafael
R
Gavaldá
Joan
J
Llinares
Pedro
P
D000328:Adult; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein / Q000009:adverse effects / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D006801:Humans; D016031:Liver Transplantation / Q000009:adverse effects; D009181:Mycoses / Q000188:drug therapy* / Q000517:prevention & control; D011183:Postoperative Complications / Q000188:drug therapy / Q000382:microbiology*; D012107:Research Design
D000935:Antifungal Agents; D053446:CASP8 and FADD-Like Apoptosis Regulating Protein